NCT01284478

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Northern California Retina Vitreous Associates · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery

Conditions

• Pseudophakic Cystoid Macular Edema,
• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Dexamethasone Implant	Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2011-01-27
• Last updated: 2012-10-04

Locations

1 site across 1 country: United States